AFT gains Australian registration for intravenous Maxigesic

AFT gains Australian registration for intravenous Maxigesic
Jenny Ruth
By Jenny Ruth July 24 (BusinessDesk) - AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration. The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution. The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, Sou...

More Listed Companies

How ‘shareholder value’ became a Wall Street mantra
Policy

How ‘shareholder value’ became a Wall Street mantra

Michael Jensen inspired the transformation of capitalism. Was he a hero or a villain?

Bloomberg 13 Apr 2024
How many boards should a director sit on?
Listed Companies

Simon Robertson: How many boards should a director sit on?

An attempt to judge the composition trends in NZX boards is challenging.

Simon Robertson 13 Apr 2024
Wellington council picks Precinct for major civic square project
Property

Wellington council picks Precinct for major civic square project

Firm will fund and build the new five-star green building.

Staff reporters 11 Apr 2024
Numbers and letters for investors
Markets

Simon Robertson: Numbers and letters for investors

A plea for standardised financial reporting from NZX-listed companies.

Simon Robertson 02 Mar 2024